Acquired Hemophilia A Pipeline Expands with 10+ Novel Therapies in Development
Global Acquired Hemophilia A pipeline comprises over 10 companies developing innovative therapies across various clinical stages, according to DelveInsight's 2025 report.
Centessa Pharmaceuticals Appoints Stephen Kanes as Chief Medical Officer to Advance Orexin Agonist Program
Centessa Pharmaceuticals appointed Stephen Kanes as Chief Medical Officer, leveraging his 30+ years of experience in neuroscience and drug development.
Centessa Pharmaceuticals Initiates Phase 2 Trial of ORX750 for Sleep-Wake Disorders
Centessa Pharmaceuticals has commenced a Phase 2 clinical trial of ORX750 for narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), and idiopathic hypersomnia.
Hemophilia A and B Pipeline Advances with Novel Therapies in Clinical Trials
• Several companies are actively developing novel therapies for Hemophilia A and B, with many in various phases of clinical trials, showing promise for improving treatment options. • TiumBio Co., Ltd. has submitted a Clinical Trial Application to initiate a Phase 1b investigation of TU7710, a new recombinant activated factor VII for hemophilia patients with inhibitors. • The FDA approved ALTUVIIIO (efanesoctocog alfa) in February 2023, a factor VIII replacement therapy for adults and children with Hemophilia A, for routine prophylaxis and on-demand treatment. • BioMarin received FDA approval for Roctavian in June 2023, a single-dose gene therapy for severe Hemophilia A, marking a significant advancement in treatment.
Centessa's ORX750 Advances to Phase 2 for Narcolepsy and Idiopathic Hypersomnia After Promising Phase 1 Results
Centessa Pharmaceuticals' ORX750, an orexin receptor 2 (OX2R) agonist, demonstrated significant improvements in wakefulness in sleep-deprived healthy volunteers.